G2PR has built a strong track record in helping our clients
Ways G2PR has helped clients recently, a snapshot…
-
Illuminating path together to better access
PROJECT
Manage cost-effectiveness modelling of large vendor for a novel molecule in a rare immunology disease
APPROACH
Understand work done thus far, and relationships
Drive together to consensus on what good looks like
Prepare for expert validation & NICE scientific advice
OUTCOMES
Global & UK teams achieved consensus on tough issue
NICE scientific advice submission, on time
Additional expert validation submitted
-
Strategic clarity, tactical course-correction
PROJECT
Evidence gap identification and a plan to address them 18 months pre-launch, in rare sarcoma
APPROACH
Understand current evidence and plan
Gap identification, iteration, alignment, validation
Prioritise evidence generation by need and impact
OUTCOMES
Place in therapy in key markets needed re-definition
Choice of comparator would change in lockstep
PFS to OS modelling, cross-over design mitigation next
-
Values-aligned price and access guidance
PROJECT
Global price guidance development and access strategy generation as a true partner, in ultra-rare haematology
APPROACH
Understand price expectations and HEOR evidence
Shape value narrative: match evidence, expectations
Ensure ambitious price guidance while being achievable
OUTCOMES
Created together ambitious values-aligned guidance
Ultra-rare nature of condition reflected practically
Generated options that empower local affiliates
-
Relaunching paediatric neurology medicines
PROJECT
Relaunch strategy of two essential paediatric neurology drugs post patent expiry
APPROACH
Understand client capabilities
Understand NHS prescribing
Prioritise accounts with maximum potential
OUTCOMES
Client quickly deployed recommendations
Sales increased beyond client expectations
Sought similar in other European countries
-
Pioneering early access scheme for a rare disease medicine
PROJECT
First early access to medicines scheme project for a mid-sized pharma bringing together local and global
APPROACH
Bring together cross-functional team colleagues
Address uncertainty, build internal sponsorship
Liaise with MHRA, NICE, NHS
OUTCOMES
Promising designation achieved in 7 weeks
Stage 1 contracts signed in 5 weeks from then
Stage 2 NHS engagement done before Phase 3 results
-
Comprehensive literature review - COVID therapies
PROJECT
Comprehensive literature review of COVID therapies to ensure health tech appraisal (HTA) preparedness
APPROACH
Defined protocol, through iterations
Refined sensitive & specific searches
Strict study selection, PRISMA diagrams
OUTCOMES
Enabled early identification of two relevant studies
Ensured comparator preparedness
Facilitated quicker submission